Prostate cancer
138 results
1 - 100
Screening for prostate cancer- Lycopene for the prevention of prostate cancer
- Bisphosphonates for advanced prostate cancer
- 5‐alpha‐reductase inhibitors for prostate cancer prevention
- Hypofractionation for clinically localized prostate cancer
- Chemotherapy for hormone‐refractory prostate cancer
- Intermittent versus continuous androgen suppression for prostatic cancer
- Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer
- Primary cryotherapy for localised or locally advanced prostate cancer
- Adjuvant radiotherapy following radical prostatectomy for prostate cancer
- Radical prostatectomy versus deferred treatment for localised prostate cancer
- Degarelix for treating advanced hormone‐sensitive prostate cancer
- Psychosocial interventions for men with prostate cancer: Cochrane systematic review
- Maximal androgen blockade for advanced prostate cancer: Cochrane systematic review
- Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
- Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
- Neo‐adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
- Laparoscopic and robotic‐assisted versus open radical prostatectomy for the treatment of localised prostate cancer
- Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
- Low-dose rate brachytherapy for men with localized prostate cancer: Cochrane systematic review
- Prediction of disease specific and overall survival in men with prostate cancer using the Decipher assay
- Posterior musculofascial reconstruction in robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer
- Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
- Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
- Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
- Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
- Antibiotic prophylaxis for transrectal prostate biopsy: Cochrane systematic review
- Tamsulosin for benign prostatic hyperplasia: Cochrane systematic review
- Conservative management for postprostatectomy urinary incontinence
- Terazosin for benign prostatic hyperplasia: Cochrane systematic review
- Selenium for preventing cancer
- Conservative interventions for managing urinary incontinence after prostate surgery
- Green tea (Camellia sinensis) for the prevention of cancer
- Exercise for the management of cancer‐related fatigue in adults
- Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery
- Effects of exposure to night shift work on cancer risk in workers
- Penile rehabilitation for postprostatectomy erectile dysfunction
- The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men
- Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults
- Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy: Cochrane systematic review
- Screening for testicular cancer
- Government regulation of private health insurance